A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 53
Summary
- Conditions
- Bladder Neoplasm
- Advanced Cancer
- Urothelial Carcinoma
- Advanced Solid Tumor
- Bladder Cancer
- Bladder Disease
- Solid Tumor, Adult
- Bladder Urothelial Carcinoma
- Neoplasm, Bladder
- Locally Advanced Solid Tumor
- Neoplasm Metastasis
- Solid Tumor
- Urothelial Neoplasm
- Metastatic Bladder Cancer
- Metastatic Cancer
- Metastatic Urothelial Carcinoma
- Urothelial Carcinoma Bladder
- Neoplasm Malignant
- Neoplasms
- Solid Carcinoma
- Neoplasm, Urinary Bladder
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: Dose escalation and expansion using the revised modified Toxicity Probability Interval (mTPI-2) designMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04200963
- Collaborators
- Bristol-Myers Squibb
- Investigators
- Study Director: Jason Sager, MD Ikena Oncology
Get Well Soon